immatics Closes €34 Million Financing to Complete Phase 3 Development of IMA901 for Renal Cancer

immatics Closes €34 Million Financing toimmatics Closes €34 Million Financing to Complete Phase 3 Development of IMA901 for Renal Cancer PR Newswire TUEBINGEN, Germany, October 15, 2013 • i m m a t i c s' lead cancer vaccine IMA901 to report interim phase 3 data in 2014 and final data in 2015 • Funding secured within existing investor group immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced multi-peptide cancer vaccines that are active against cancer, today announced that it has closed a €34 million Series D financing round. The funding round was supported by existing investors including dievini Hopp Biotech holding, Wellington Partners, MIG-advised funds and AT Impf GmbH. Under the terms of the fundraising, immatics will receive the first €12 million tranche of funding immediately. The new funds will enable immatics to conclude the development of its lead vaccine IMA901, including completing all of the activities necessary to prepare for regulatory filings in the US and Europe. IMA901 - a cancer vaccine comprising 10 different tumor-associated peptides (TUMAPs) that are found to be highly over-expressed in the majority of patients suffering from renal cell carcinoma (RCC) - is in a pivotal phase 3 trial. It has orphan drug designation in the US and Europe for the treatment of RCC in HLA- A*02 positive patients.